Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Next Previous
Trial Profile

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GFB 887 (Primary)
  • Indications Diabetic nephropathies; Focal segmental glomerulosclerosis; Lipoid nephrosis
  • Focus Therapeutic Use
  • Acronyms TRACTION-2
  • Sponsors Goldfinch Bio

Most Recent Events

  • 10 Nov 2022 Status changed from recruiting to discontinued.
  • 22 Mar 2022 According to a Goldfinch Bio media release, the company will host a virtual event to discuss the recently announced preliminary clinical data from TRACTION-2 by Anthony Johnson, M.D, on March 29, 2022 at 4:00 p.m. ET; A live webcast of the event will be available under Videos & Features on the companys website at www.goldfinchbio.com. A replay of the webcast will be available on the Goldfinch Bio website following the event.
  • 28 Feb 2022 according to a Goldfinch Bio media release, results of prespecified interim analysis are expected in mid 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top